CNS and oncology appear prime targets for Proteus and Otsuka's 'digital medicines'
This article was originally published in Scrip
In another sign of the blurring boundaries between therapeutics and medical technology, Otsuka Pharmaceutical has put down its marker in the area of drug compliance management, linking up with Proteus Digital Health for the joint development and commercialisation of "digital medicines".
You may also be interested in...
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.